Literature DB >> 18273830

Acute risperidone treatment did not increase daily cigarette consumption or plasma levels of cotinine and caffeine: a pilot study.

Reiji Yoshimura1, Shingo Kakihara, Wakako Umene-Nakano, Atsuko Sugita, Hikaru Hori, Nobuhisa Ueda, Jun Nakamura.   

Abstract

Excessive cigarette smoking and caffeine intake are often seen in schizophrenic patients being treated with antipsychotic drugs, particularly typical antipsychotic drugs. Using nicotine and caffeine sometimes influences psychotic symptoms in these patients. Clozapine is the only antipsychotic drug reported to reduce the amount of cigarette smoking, however, still remains controversial of its efficacy. In the present study, we examined the effect of acute risperidone treatment on the amount of cigarette smoking and plasma levels of cotinine and caffeine in schizophrenic patients. Treatment with risperidone for 4 weeks did not increase daily cigarette consumption or plasma levels of cotinine and caffeine. The results suggest that acute risperidone treatment does not promote the intake of nicotine and caffeine at least by 4 weeks in schizophrenic patients. (c) 2008 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18273830     DOI: 10.1002/hup.928

Source DB:  PubMed          Journal:  Hum Psychopharmacol        ISSN: 0885-6222            Impact factor:   1.672


  3 in total

Review 1.  Neurotrophin strategies for neuroprotection: are they sufficient?

Authors:  Joseph P Steiner; Avindra Nath
Journal:  J Neuroimmune Pharmacol       Date:  2014-03-08       Impact factor: 4.147

Review 2.  The role of antipsychotics in smoking and smoking cessation.

Authors:  Annette M Matthews; Vanessa B Wilson; Suzanne H Mitchell
Journal:  CNS Drugs       Date:  2011-04       Impact factor: 5.749

3.  Smoking Rates and Number of Cigarettes Smoked per Day in Schizophrenia: A Large Cohort Meta-Analysis in a Japanese Population.

Authors:  Kazutaka Ohi; Takamitsu Shimada; Aki Kuwata; Yuzuru Kataoka; Hiroaki Okubo; Kohei Kimura; Toshiki Yasuyama; Takashi Uehara; Yasuhiro Kawasaki
Journal:  Int J Neuropsychopharmacol       Date:  2019-01-01       Impact factor: 5.176

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.